Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a marker of poor prognosis and a potential therapeutic target.
❓ Unknown
Commonly mutated gene could be a therapeutic target in sarcoma
Just now
November 19, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
This article is not relevant to Iranian affairs. It reports on cancer research findings from a U.S. medical institution regarding sarcoma treatment and the ATRX gene, with no connection to Iran, Iranian politics, or Iranian society.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
8 min ago •
US and Iran once practiced diplomacy through archaeology—that legacy need not lie in ruins
8 min ago •
International Research Team Proposes Security Framework for Generative AI in Biological Research
8 min ago •